Intensity Therapeutics Inc INTS

US Biotechnology

$3.09 ▼ -1.90% ($-0.06)

🎈 Low Float 🎢 High Beta

Open $2.97

Prev Close $3.15

Day Range $2.97 – $3.26

52W Range $2.80 – $15.00

Market Cap $10.40M

Beta 2.99

EPS (TTM) $-4.93

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2023-06-30
Shares Out.	3,260,000
Website	intensitytherapeutics.com ↗
Phone	13026365400
Employees	7
Revenue	$0
Gross Profit	$0
Net Income	-$3.5M
Free Cash Flow	-$9.1M
Total Assets	$10.3M
Total Liabilities	$2.6M
Equity	$7.7M

About Intensity Therapeutics Inc

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Intensity Therapeutics Inc is a publicly traded company under the ticker symbol INTS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.